Picard Medical Shareholder Notice Issued
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 10 hours ago
0mins
Should l Buy PMI?
Source: PRnewswire
- Shareholder Notice: The Gross Law Firm has issued a notice to shareholders of Picard Medical (NYSE:PMI), encouraging those who purchased shares between September 2, 2025, and October 31, 2025, to contact the firm regarding potential lead plaintiff status.
- Fraud Allegations: The complaint alleges that during the class period, Picard was involved in a fraudulent stock promotion scheme that utilized social media misinformation and insider trading through offshore accounts, artificially inflating the stock price.
- Disclosure Failures: Picard's public statements and risk disclosures omitted critical information regarding false rumors and artificial trading activities, rendering the company's positive assertions about its business and prospects misleading and lacking a reasonable basis.
- Participation Deadline: Shareholders must register for the class action by April 3, 2026, and upon registration, they will receive updates on the case's progress through portfolio monitoring software, with no costs or obligations to participate.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PMI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PMI
About PMI
Picard Medical, Inc. is a holding company that owns a 100% interest in SynCardia Systems, LLC (SynCardia). SynCardia is a medical technology company that manufactures and sells the only United States Food and Drug Administration (FDA) and Health Canada-approved implantable total artificial heart (SynCardia TAH). The SynCardia TAH is a biventricular replacement device that consists of the SynCardia TAH implant, an external pneumatic driver that delivers precisely calibrated pulses of air to drive the implant, and drivelines that connect the driver to the implant. The SynCardia TAH implant is a system that consists of two independent artificial ventricles which are powered by an external pneumatic driver. Each artificial ventricle is made of a semi-rigid polyurethane housing and a rigid polyurethane base, with a four-layer flexible polyurethane diaphragm separating the blood chamber from the air chamber.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Picard Medical and UCSF Achieve Successful Heart Transplant
- Clinical Milestone: UCSF Health successfully performed a heart transplant on a patient previously supported by Picard Medical's SynCardia Total Artificial Heart, marking a significant advancement in treating advanced biventricular heart failure and demonstrating the growing clinical adoption of this technology.
- Patient Background: The 37-year-old patient was admitted in August 2025 with end-stage heart failure and underwent a six-hour surgery to implant the SynCardia Total Artificial Heart, becoming the fifth patient at UCSF to receive this device, highlighting the hospital's leadership in heart transplantation.
- Surgical Team: The procedure was led by Dr. Amy Fiedler and Dr. Jason W. Smith, with UCSF hosting one of the largest heart transplant programs in the country and being the only active program in Northern California to fully implant mechanical hearts, reinforcing its authority in cardiac surgery.
- Future Development: Picard Medical is advancing the development of the Emperor TAH, a next-generation device aimed at expanding access to long-term mechanical circulatory support, reflecting the company's commitment to providing better treatment options for patients with advanced heart failure, aligning with its mission.
See More
Picard Medical Faces Class Action for Securities Fraud
- Class Action Filed: Pomerantz LLP has announced a class action lawsuit against Picard Medical, alleging that the company and certain officers engaged in securities fraud or other unlawful business practices, with investors having until April 3, 2026, to apply as Lead Plaintiff.
- Stock Price Surge: Leading up to October 23, 2025, Picard's stock price skyrocketed from its IPO price of $4.00 to an all-time high of $13.68, despite the absence of any fundamental news, indicating irrational market behavior.
- Social Media Manipulation: Investigations revealed that Picard's stock was subject to an illicit social media promotion scheme, where impersonators posing as legitimate financial advisors made sensational but unfounded claims, creating a buying frenzy among retail investors.
- Severe Legal Consequences: Pomerantz LLP, a prominent firm in securities class litigation with a long history of recovering multimillion-dollar damages for victims, suggests that this case could have significant financial and reputational repercussions for Picard Medical.
See More
Picard Medical Shareholder Notice Issued
- Shareholder Notice: The Gross Law Firm has issued a notice to shareholders of Picard Medical (NYSE:PMI), encouraging those who purchased shares between September 2, 2025, and October 31, 2025, to contact the firm regarding potential lead plaintiff status.
- Fraud Allegations: The complaint alleges that during the class period, Picard was involved in a fraudulent stock promotion scheme that utilized social media misinformation and insider trading through offshore accounts, artificially inflating the stock price.
- Disclosure Failures: Picard's public statements and risk disclosures omitted critical information regarding false rumors and artificial trading activities, rendering the company's positive assertions about its business and prospects misleading and lacking a reasonable basis.
- Participation Deadline: Shareholders must register for the class action by April 3, 2026, and upon registration, they will receive updates on the case's progress through portfolio monitoring software, with no costs or obligations to participate.
See More
Reminder of Securities Fraud Lawsuit for Picard Medical Investors
- Stock Price Crash: On October 23, 2025, Picard Medical's stock plummeted approximately 70% during after-hours trading, dropping from $13.20 to $3.99 per share, resulting in significant losses for investors and reflecting a severe lack of confidence in the company's prospects.
- Fraudulent Promotion Exposed: Investigations revealed that Picard's stock was targeted by a fraudulent social media promotion scheme, where impersonators of financial advisors spread false information in online forums and social media to artificially inflate the stock price, exacerbating investor losses.
- Lawsuit Overview: The class action lawsuit alleges that throughout the class period, defendants made materially false and misleading statements and failed to disclose adverse facts about the company's business and prospects, leading investors to misunderstand the company's actual situation.
- Legal Action Deadline: Investors must file a motion by April 3, 2026, to request the court to appoint them as lead plaintiff if they meet specific legal requirements, ensuring their rights are protected in the ongoing lawsuit.
See More
Faruqi & Faruqi Investigates Securities Claims Against Picard Medical
- Legal Claim Investigation: Faruq & Faruq LLP is investigating potential claims against Picard Medical, specifically targeting investors who purchased securities between September 2, 2025, and October 31, 2025, aiming to provide legal support for affected investors.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to contact him directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal rights and options regarding the situation.
- Class Action Deadline: Investors should note that the deadline to seek the role of lead plaintiff in the federal securities class action against Picard Medical is April 3, 2026, making this timeline critical for affected investors.
- Company Background: Picard Medical (NYSE:PMI) is facing legal challenges, and the investigation by Faruq & Faruq LLP may impact its stock price and market confidence, prompting investors to closely monitor developments.
See More
Class Action Lawsuit Announced for Picard Medical, Inc.
- Class Action Initiation: Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Picard Medical securities between September 2 and October 31, 2025, alleging that the company made misleading statements that caused investor losses during this period.
- Compensation Structure: Investors participating in the lawsuit may receive compensation without any upfront costs, indicating that Rosen Law Firm operates on a contingency fee basis, which alleviates financial burdens for investors.
- Counsel Selection Importance: The firm emphasizes the importance of selecting qualified legal counsel, noting its track record of recovering over $438 million for investors in 2019 alone, showcasing its strength in securities class action litigation.
- Case Details Unveiled: The lawsuit alleges that Picard Medical failed to disclose critical information regarding its business and securities trading, including fraudulent stock promotions and insider trading, which misled investors about the company's prospects and could impact future stock performance.
See More
Picard Medical and UCSF Achieve Successful Heart Transplant
- Clinical Milestone: UCSF Health successfully performed a heart transplant on a patient previously supported by Picard Medical's SynCardia Total Artificial Heart, marking a significant advancement in treating advanced biventricular heart failure and demonstrating the growing clinical adoption of this technology.
- Patient Background: The 37-year-old patient was admitted in August 2025 with end-stage heart failure and underwent a six-hour surgery to implant the SynCardia Total Artificial Heart, becoming the fifth patient at UCSF to receive this device, highlighting the hospital's leadership in heart transplantation.
- Surgical Team: The procedure was led by Dr. Amy Fiedler and Dr. Jason W. Smith, with UCSF hosting one of the largest heart transplant programs in the country and being the only active program in Northern California to fully implant mechanical hearts, reinforcing its authority in cardiac surgery.
- Future Development: Picard Medical is advancing the development of the Emperor TAH, a next-generation device aimed at expanding access to long-term mechanical circulatory support, reflecting the company's commitment to providing better treatment options for patients with advanced heart failure, aligning with its mission.
See More
Picard Medical Faces Class Action for Securities Fraud
- Class Action Filed: Pomerantz LLP has announced a class action lawsuit against Picard Medical, alleging that the company and certain officers engaged in securities fraud or other unlawful business practices, with investors having until April 3, 2026, to apply as Lead Plaintiff.
- Stock Price Surge: Leading up to October 23, 2025, Picard's stock price skyrocketed from its IPO price of $4.00 to an all-time high of $13.68, despite the absence of any fundamental news, indicating irrational market behavior.
- Social Media Manipulation: Investigations revealed that Picard's stock was subject to an illicit social media promotion scheme, where impersonators posing as legitimate financial advisors made sensational but unfounded claims, creating a buying frenzy among retail investors.
- Severe Legal Consequences: Pomerantz LLP, a prominent firm in securities class litigation with a long history of recovering multimillion-dollar damages for victims, suggests that this case could have significant financial and reputational repercussions for Picard Medical.
See More
Picard Medical Shareholder Notice Issued
- Shareholder Notice: The Gross Law Firm has issued a notice to shareholders of Picard Medical (NYSE:PMI), encouraging those who purchased shares between September 2, 2025, and October 31, 2025, to contact the firm regarding potential lead plaintiff status.
- Fraud Allegations: The complaint alleges that during the class period, Picard was involved in a fraudulent stock promotion scheme that utilized social media misinformation and insider trading through offshore accounts, artificially inflating the stock price.
- Disclosure Failures: Picard's public statements and risk disclosures omitted critical information regarding false rumors and artificial trading activities, rendering the company's positive assertions about its business and prospects misleading and lacking a reasonable basis.
- Participation Deadline: Shareholders must register for the class action by April 3, 2026, and upon registration, they will receive updates on the case's progress through portfolio monitoring software, with no costs or obligations to participate.
See More
Reminder of Securities Fraud Lawsuit for Picard Medical Investors
- Stock Price Crash: On October 23, 2025, Picard Medical's stock plummeted approximately 70% during after-hours trading, dropping from $13.20 to $3.99 per share, resulting in significant losses for investors and reflecting a severe lack of confidence in the company's prospects.
- Fraudulent Promotion Exposed: Investigations revealed that Picard's stock was targeted by a fraudulent social media promotion scheme, where impersonators of financial advisors spread false information in online forums and social media to artificially inflate the stock price, exacerbating investor losses.
- Lawsuit Overview: The class action lawsuit alleges that throughout the class period, defendants made materially false and misleading statements and failed to disclose adverse facts about the company's business and prospects, leading investors to misunderstand the company's actual situation.
- Legal Action Deadline: Investors must file a motion by April 3, 2026, to request the court to appoint them as lead plaintiff if they meet specific legal requirements, ensuring their rights are protected in the ongoing lawsuit.
See More
Faruqi & Faruqi Investigates Securities Claims Against Picard Medical
- Legal Claim Investigation: Faruq & Faruq LLP is investigating potential claims against Picard Medical, specifically targeting investors who purchased securities between September 2, 2025, and October 31, 2025, aiming to provide legal support for affected investors.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to contact him directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal rights and options regarding the situation.
- Class Action Deadline: Investors should note that the deadline to seek the role of lead plaintiff in the federal securities class action against Picard Medical is April 3, 2026, making this timeline critical for affected investors.
- Company Background: Picard Medical (NYSE:PMI) is facing legal challenges, and the investigation by Faruq & Faruq LLP may impact its stock price and market confidence, prompting investors to closely monitor developments.
See More
Class Action Lawsuit Announced for Picard Medical, Inc.
- Class Action Initiation: Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Picard Medical securities between September 2 and October 31, 2025, alleging that the company made misleading statements that caused investor losses during this period.
- Compensation Structure: Investors participating in the lawsuit may receive compensation without any upfront costs, indicating that Rosen Law Firm operates on a contingency fee basis, which alleviates financial burdens for investors.
- Counsel Selection Importance: The firm emphasizes the importance of selecting qualified legal counsel, noting its track record of recovering over $438 million for investors in 2019 alone, showcasing its strength in securities class action litigation.
- Case Details Unveiled: The lawsuit alleges that Picard Medical failed to disclose critical information regarding its business and securities trading, including fraudulent stock promotions and insider trading, which misled investors about the company's prospects and could impact future stock performance.
See More
